Study results show BNC210 more effective in treating stressed rats with Phase Ib trials scheduled for later this year
Adelaide biotech Bionomics has presented the results of preclinical and clinical data for its anti-anxiety compound BNC210, demonstrating that the drug is more effective in treating stressed rats than the current market leader valium (Diazapem).
Clinuvel plans to start clinical trials on sufferers of skin pigmentation disorder vitiligo
Melbourne biotech
Clinuvel announced today that it plans to conduct clinical trials of its UV protection drug Scenesse as a treatment for the skin pigmentation disorder vitiligo.
A xenotransplantation technology using insulin producing cells from pigs offers new hope for diabetes sufferers.
Back when Living Cell Technologies's (LCT) current Medical Director and Founder, Professor Bob Elliott, was working in his Auckland clinic, he decided that the treatments available for patients with Type I diabetes simply weren't good enough.
Early indications positive for treatment against Type 1 diabetes
Xenotransplantation specialists Living Cell Technologies (LCT) announced today that promising results from a Phase II clinical trial of its cell implant Diabecell in diabetes patients in New Zealand had prompted the country’s health regulator to approve the addition of four more patients.
PAT-SM6 human antibody to be trailed on 10 Australian melanoma sufferers
Melbounre biotech Patrys announced today that the Royal Adelaide Hospital has approved a clinical trial evaluating its PAT-SM6 natural human antibody as a treatment for melanoma.
The Human Proteome Organisation (HPUO) 2010 World Congress and the Human Proteome Project feature in this issue, along with proteomics, synthetic biology, genetics and genomics, and next generation genome sequencing.
The July/August edition of Australian Life Scientist is out now. The issue takes an in-depth look at the happenings at the upcoming Human Proteome Organisation (HPUO) 2010 World Congress, which will host the launch of the long awaited Human Proteome Project.
Clincal trial setback while high costs point to reimbursement restrictions
Botox was approved in the UK this month for the treatment of migraines, however, the high costs of the cosmetic treatment as well as lingering safety concerns may restrict its ability to penetrate this new market.
US clinical trial of anti-viral BTA798 to treat human rhinovirus to coincide with onset of northern hemisphere flu season.
Biota Holdings today commenced a 400-member trial in the US of its anti-viral drug BTA798 on sufferers of
asthma who present with cold symptoms.
MDMA shown to be far more effective than SSRIs and therapy
US researchers have published the results of the first ever clinical trial examining the effectiveness of MDMA in treating sufferers of post traumatic stress disorder (PTSD).
Australian researchers identify two non-chemo alternatives for bowel cancer treatment
The results of an Australian clinical trial assessing two new treatment approaches for bowel cancer patients unable to withstand chemotherapy were published today in the prestigious medical journal, the Journal of Clinical Oncology.
QRxPharma's dual-opioid, MoxDuo, completes first of two pivotal Phase III trials, on track for NDA by end of 2010.
QRxPharma is another step closer to bringing its immediate release dual-opioid pain therapy, MoxDuoIR, to the market with the completion of one of two pivotal Phase III clinical trials held in the United States.
The mechanism linking breast cancer to stem cells has been uncovered, which could lead to new cancer treatments.
The mechanism linking breast cancer to stem cells has been uncovered, which could lead to new cancer treatments.
A reluctance to publish negative results is leading to a troubling bias in scientific journals.
A reluctance to publish negative results is leading to a troubling bias in scientific journals.
Phase II trial to test effectiveness of afamelanotide in treating erythropoietic protoporphyria.
Phase II trial to test effectiveness of afamelanotide in treating erythropoietic protoporphyria.
New clinical trial for type I diabetes treatment using xenotransplantation of pig cells to begin in New Zealand.
New clinical trial for type I diabetes treatment using xenotransplantation of pig cells to begin in New Zealand.
